Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Advanced Solid Tumor 13Leukemia, Myeloid, Acute 10Carcinoma, Non-Small-Cell Lung 7Advanced Solid Tumors 7Breast Neoplasms 6Solid Tumor 5Pancreatic Neoplasms 5Melanoma 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Neoplasms 4Neoplasm Metastasis 4Lymphoma, Non-Hodgkin 4Solid Tumors 3Recurrence 3Myelodysplastic Syndromes 3Lung Neoplasms 3Leukemia, Biphenotypic, Acute 3Esophageal Neoplasms 3Carcinoma, Hepatocellular 3Biliary Tract Neoplasms 3Advanced Malignant Solid Tumor 3Advanced Lung Cancer 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2

Interventions

pembrolizumab 1Ribavirin 1Nivolumab 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Malignant Solid Tumor × Injections × Clear all
NCT07136142 2025-08-22

A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Not yet recruiting
150 enrolled
Other solid neoplasm

Malignant Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡